The Current Ratio as of September 2024 (TTM) for Kymera Therapeutics, Inc. (KYMR) is 8.45

According to Kymera Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.45. This represents a change of 17.82% compared to the average of 7.18 of the last 4 quarters.

Kymera Therapeutics, Inc. (KYMR) Historical Current Ratio (quarterly & annually)

How has KYMR Current Ratio performed in the past?

The mean historical Current Ratio of Kymera Therapeutics, Inc. over the last ten years is 5.59. The current 8.45 Current Ratio has changed 15.03% with respect to the historical average. Over the past ten years (40 quarters), KYMR's Current Ratio was at its highest in in the March 2024 quarter at 9.57. The Current Ratio was at its lowest in in the September 2019 quarter at 0.

Kymera Therapeutics, Inc. (KYMR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Kymera Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kymera Therapeutics, Inc. (KYMR) Average Current Ratio

How has KYMR Current Ratio performed in the past?

The current Current Ratio of Kymera Therapeutics, Inc. (KYMR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kymera Therapeutics, Inc. (KYMR) Current Ratio vs. Peers

How is KYMR’s Current Ratio compared to its peers?

Kymera Therapeutics, Inc.’s Current Ratio is greater than Foghorn Therapeutics Inc. (5.69), greater than Shattuck Labs, Inc. (7.62), greater than Monte Rosa Therapeutics, Inc. (6.56), greater than Nurix Therapeutics, Inc. (5.57), less than Revolution Medicines, Inc. (15.42), greater than C4 Therapeutics, Inc. (5.09), less than Agios Pharmaceuticals, Inc. (10.09), less than Century Therapeutics, Inc. (10.62), less than Edgewise Therapeutics, Inc. (30.24), less than Mineralys Therapeutics, Inc. (11.20), less than Cullinan Oncology, Inc. (28.87), less than Eliem Therapeutics, Inc. (60.41), greater than Prelude Therapeutics Incorporated (7.83),

Build a custom stock screener for Kymera Therapeutics, Inc. (KYMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kymera Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kymera Therapeutics, Inc. (KYMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kymera Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.